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Introduction
Vaccination of infants against diphtheria, tetanus, pertussis and polio is well established in Korea, with coverage rates of the third DTPa (combined diphtheria-tetanus-acellular pertussis vaccine) dose at 94% 1) . Acellular pertussis vaccines were introduced in Korea in 1982 2, 3) . The vaccines have been widely used from 1984 4) and are considered effective in preventing pertussis disease in the country. Acellular pertussis vaccines have an improved tolerability profile compared to whole cell pertussis (DTPw) vaccines 5, 6) . In Korea, after the transition from DTPw to DTPa, the five-dose coverage rates for DTPa (three primary doses and two booster doses) rose from 65% to 81% between 2004 and 2007 7) , correlating with improved diphtheria, tetanus and pertussis disease control 8) .
Reported cases of pertussis currently remain low in Korea. In 2006 there were only 17 pertussis cases reported to the World Health Organization 1) . However, a report suggests that as in other countries with longstanding and widespread pertussis vaccination, pertussis disease may be more common than expected in unvaccinated infants, and may frequently go unrecognized 9) . These data highlight the importance of continued high vaccination coverage against pertussis using effective and safe vaccines in Korea.
No polio cases due to wild poliovirus have been recorded in Korea since 1983 10) and Korea was declared free of wild poliovirus in 2000 11) . The Korean Advisory Committee on Immunization Practice moved to an all-IPV (inactivated poliovirus vaccine) schedule in 2005 10) . However, the intro-duction of IPV into the Korean vaccination schedule increased the number of injections given to children at those vaccination visits when poliomyelitis vaccine was required. Data from the United States and Germany suggest that both the timeliness of vaccination and coverage rates until 24 months of age are improved when children receive combination vaccines compared to separate vaccines that require additional injections 12, 13) . Thus, administration of the DTPa and IPV vaccines in a single injection has the potential to promote compliance with vaccination schedules by reducing the number of injections required for immunization, thereby improving subject/ parents and physician acceptance.
The combined DTPa-IPV vaccine (Infanrix TM IPV, GlaxoSmithKline Biologicals, Belgium) provides vaccination against diphtheria, tetanus, pertussis as well as poliovirus, using IPV, in a single injection.
DTPa-IPV has been licensed in Italy for primary vaccination use of infants and/or booster vaccination up until the age of 13 years. In a household contact study in Germany, the protective efficacy of the DTPa component, Infanrix TM , against WHO-defined pertussis disease was shown to be 89% 14) . These results were confirmed in a large randomized placebo-controlled trial in Italy, where the protective efficacy was 84% 15) .
The present study evaluated the immunogenicity, safety and reactogenicity of the combined DTPa-IPV vaccine compared with co-administration of DTPa and IPV vaccines at separate injection sites to healthy Korean infants at 2, 4 and 6 months of age. All vaccines were administered as intramuscular injections into the anterolateral region of the thigh.
Materials and Methods

Study design and study subjects
Analysis of immunogenicity
Blood samples were collected from all infants prior to vaccination and one month post-dose 3
(range: 21-48 days) for measurement of antibody concentrations against all vaccine antigens using standard methods. Antibodies against diphtheria, tetanus and pertussis antigens were measured using an enzyme-linked immunosorbent assay (ELISA).
Infants with anti-diphtheria and anti-tetanus antibody concentrations 0.1 IU/mL were considered ≥ protected 16, 17) . The assay cut-off for pertussis antibodies was 5 ELISA Units (EL.U)/mL. As there is no established serological correlate of protection against pertussis, a vaccine response to pertussis was defined as the appearance of antibodies in initially seronegative infants or maintenance of pre-vaccination antibody concentration in infants who were seropositive prior to vaccination taking into account the natural decrease of maternal antibodies 18) . Neutralizing antibodies to poliovirus types 1, 2 and 3 were determined using a modification of the WHO micro-neutralization test method 19) with a titer of 8 considered protective.
Analysis of safety
Parents/guardians were provided with diary cards for loss of appetite grade 0: usual appetite; grade 1: ate less than usual/no effect on normal activity; grade 2: ate less than usual/interfered with normal activity and grade 3: did not eat at all.
All other (unsolicited) symptoms occurring for 31 days after each dose were recorded. Serious adverse events (SAEs) were defined as any untoward medical occurrence that was life-threatening, resulted in death, required hospitalization, resulted in disability/incapacity or was a congenital anomaly.
The SAEs were recorded throughout the study period.
Statistical analysis
The primary objective of the study was to de- With 191 subjects per group, the study had an overall power of 89% to meet the primary objectives.
After adjusting for dropouts and eliminations, 225 subjects per group were to be enrolled. 
Results
A total of 458 infants were enrolled and 452 infants were vaccinated (Fig. 1) 
Immunogenicity
One month post-dose 3, all infants were seropro- tected with respect to anti-diphtheria, anti-tetanus and anti-polio type 1 antibodies. At least 99.5% of subjects in both groups were seroprotected against poliovirus type 2 and type 3 antigens ( Table 2 ).
The vaccine response to PT, FHA and PRN was observed in at least 98.6% of subjects in both groups ( Table 2 ).
The observed antibody GMC (geometric mean concentration)/GMTs (geometric mean titers) against each vaccine antigen were higher in DTPa-IPV group than in the DTPa+IPV group.
Non-inferiority of the combined DTPa-IPV vaccine with separately administered DTPa+IPV was established according to all pre-specified criteria (Table 3 ).
Reactogenicity and safety
Redness at the injection site and irritability were the most commonly reported local and systemic solicited symptoms in both vaccine groups ( Table 5 . Causally related symptoms were reported after 2.6% of DTPa-IPV doses and 3.0% of DTPa+IPV doses. In both groups, 
Discussion
This randomized controlled study confirmed that the DTPa-IPV combination vaccine was highly immunogenic, with more than 99.5% of subjects [20] [21] [22] [23] [24] [25] in which the im- 
